Aug 07, 2013, 10.14 AM | Source: CNBC-TV18
Tirthankar Patnaik of Religare Capital Markets, in an interview to CNBC-TV18, estimates that the market to dip before rise and recommends bets on IT, pharmaceutical stocks.
Tirthankar Patnaik (more)
India Strategist, Mizuho Bank | Capital Expertise: Equity - Fundamental
Speaking to CNBC-TV18, Patnaik recommends investors to bet on IT and pharmaceutical stocks to take cover in a bearish market.
Below is the edited transcript of the interview on CNBC-TV18
Q: With the rupee making fresh lows almost every week, do you expect more measures by the Reserve Bank of India (RBI)?
A: To estimate if the RBI will tighten interest rates, the two questions that need to be answered is if there are permanent measures to control the rupee and if the central bank has the means to maintain such measures. With the answer being negative in both cases, we expect more pain from the central bank as the rupee goes weaker.
Q: There has seen a major sell-off in the equity markets today. Do you expect more downside?
A: Logically, the markets should bear the brunt of lower growth and reflect the reality that India no longer commands a premium. Logic demands that the market should be down 10 percent atleast from the current levels.
But liquidity and differentiation in market valuations have managed to defy this trend. We believe that the struggle for private banks is not over yet and urban consumption could fall this year. Rural consumption should see some support from strong agricultural growth. In other words, growth will fall before it starts to rise.
Q: Where should investors go? Where should they seek cover in such a bearish environment?
A: For the last many quarters, we have recommended positioning on a dollar-dominated portfolio. So, we are overweight on IT and pharma. Investing in telecom is also another prudent option as the sector will deliver earnings visibility. It is best to be neutral on banks.
Nagreeka Cap standalone Dec '15 sales at Rs -12.31 crore
Nagreeka Capital and Infrastructure has reported a
Mindvision Cap standalone Dec '15 sales at Rs 0.24 crore
Mindvision Capital has reported a sales total inco
Hold Cipla; on track to meet 20%+ EBITDA margins in'16: Religare
Praful Bohra of Religare is confident of the compa
Elixir Cap consolidated Dec '15 sales at Rs 1.66 crore
Elixir Capital has reported a consolidated total i
India Consumer-RM cost continues to ease in Dec15: Religare
Religare has come out with its report on India Con
Mkt slowly forming a bottom; seeing a technical sell-off: Pros
Vaibhav Kapoor of IL&FS believes the market is slo
Fundamental support for mkt missing; like banks: Mizuho Bank
Speaking to CNBC-TV18, Tithankar Patnaik of Mizuho
See further pain for mkt, no intraday trade in Bank Nifty: Pros
We are not in a mild recession but from a macro pe